Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial)

Autor: Ton Dhondt, Liesbeth Vleugel, Eelko Hak, Maarten J. Postma, Marjolein Boshuisen, Laura Breuning, Arne J. Risselada, Rob M. Kok, Paul A. F. Jansen, Bob Wilffert, J. G. Maring, Harry Venema, Rob J. van Marum, Elizabeth J J Berm, Jacobus Brouwers, Richard C. Oude Voshaar, Hans Mulder

Publikováno v: TRIALS, 16(1):37. BMC
Trials, 16. BioMed Central
Trials [E], 16(1). BioMed Central
Berm, E J J, Hak, E, Postma, M, Boshuisen, M, Breuning, L, Brouwers, J R B J, Dhondt, T, Jansen, P A F, Kok, R M, Maring, J G, van Marum, R J, Mulder, H, Voshaar, R C O, Risselada, A J, Venema, H, Vleugel, L & Wilffert, B 2015, ' Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial) ', Trials, vol. 16, pp. 37 . https://doi.org/10.1186/s13063-015-0561-0
Trials

Background Nortriptyline and venlafaxine are commonly used antidepressants for treatment of depression in older patients. Both drugs are metabolized by the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme and guidelines for dose adaptations based on t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af11c7066fb8ca584c314b6ee3741d82
https://research.rug.nl/en/publications/d5135c93-5d58-49c8-854b-047434bf8d51